PODCAST: European businesses glum on China, and AstraZeneca weighs spin-off for Chinese unit
By Doug Young & Rene Vanguestaine
The latest annual survey by the EU Chamber of Commerce in China shows revenue fell for more European businesses’ China operations last year. Is this a watershed moment for China’s economy, showing the days of western enthusiasm for investing in the country will never return to pre-covid levels? And AstraZeneca has become the latest major company to weigh a potential spinoff of its China unit. Is this the beginning of a trend?
About China Inc
China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.
Subscribe to China Inc on your favorite app:
Related Articles
Alibaba’s Sun Art Sale, and a China-Kazakhstan Dual Listing
A tea party resumes and the allure of Nvidia
Two IPOs: One in Autonomous Driving and One in Gold
RELATED ARTICLES
-
CHINA BULLETIN: Fiscal Revenue, Land Sales Fall in April
- CHINA BULLETIN: Manufacturing Déjà Vu
-
Is Baozun’s risky leap into brand management starting to pay off?
9991.HK BZUN.US
-
BYD drives ahead on European journey, undeterred by new tariffs
1211.HK 002594.SHE
- CHINA BULLETIN: Blinken, Yellen Talk Up China Challenge
